General Information of Drug (ID: DMR6Z2N)

Drug Name
Des-AA1,2,4,13-[D-Trp8]SRIF Drug Info
Synonyms CHEMBL410047; Des-AA1,2,4,13-[D-Trp8]SRIF
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
44388125
TTD Drug ID
DMR6Z2N

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Pasireotide DMHM7JS Cushing disease 5A70 Approved [2]
ODT-8 DMBWO5T N. A. N. A. Phase 3 [1]
FR-121196 DMNRUGA Alzheimer disease 8A20 Terminated [3]
SOMATOSTATIN DMIOFQE Acromegaly 5A60.0 Investigative [4]
Des-AA1,2,5-[D-Trp8,Tyr11]SRIF DM7MZ2V Discovery agent N.A. Investigative [5]
Des-AA1,2,5,12,13-[D-Trp8]SRIF DM1KJAE Discovery agent N.A. Investigative [1]
SRIF-28 DM0OM9L Discovery agent N.A. Investigative [6]
99mTc-MIP-1407 DMYPD5L Neuroendocrine cancer 2B72.1 Investigative [3]
Des-AA1,2,4,12,13-[D-Trp8]SRIF DMMWDC5 Discovery agent N.A. Investigative [1]
Cytotoxin Peptide Conjugate DM7SVLZ Discovery agent N.A. Investigative [7]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Pasireotide DMHM7JS Cushing disease 5A70 Approved [8]
Lutetium Lu 177 dotatate DMN1XVC Neuroendocrine cancer 2B72.1 Approved [9]
ODT-8 DMBWO5T N. A. N. A. Phase 3 [1]
FR-121196 DMNRUGA Alzheimer disease 8A20 Terminated [3]
SOMATOSTATIN DMIOFQE Acromegaly 5A60.0 Investigative [4]
Des-AA1,2,5-[D-Trp8,Tyr11]SRIF DM7MZ2V Discovery agent N.A. Investigative [5]
Des-AA1,2,5,12,13-[D-Trp8]SRIF DM1KJAE Discovery agent N.A. Investigative [1]
SRIF-28 DM0OM9L Discovery agent N.A. Investigative [6]
99mTc-MIP-1407 DMYPD5L Neuroendocrine cancer 2B72.1 Investigative [3]
Des-AA1,2,4,12,13-[D-Trp8]SRIF DMMWDC5 Discovery agent N.A. Investigative [1]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Pasireotide DMHM7JS Cushing disease 5A70 Approved [10]
Octreotide DMHIDCJ Acromegaly 5A60.0 Approved [11]
Lanreotide acetate DMG6ZU4 Acromegaly 5A60.0 Approved [12]
Ga-68-DOTATOC DMZ0P95 Diagnostic imaging N.A. Approved [13]
Copper dotatate Cu-64 DM26KR1 Diagnostic imaging N.A. Approved [14]
ODT-8 DMBWO5T N. A. N. A. Phase 3 [1]
Paltusotine DM97IN2 Acromegaly 5A60.0 Phase 3 [15]
TBR-760 DMM5BVG Pituitary adenoma 2F37.0 Phase 2 [16]
Re-188-P-2045 DM614BA Lung cancer 2C25.0 Phase 1/2 [17]
PEN-221 DMMAUOK Neuroendocrine cancer 2B72.1 Phase 1/2 [18]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
ODT-8 DMBWO5T N. A. N. A. Phase 3 [1]
177Lu-DOTATATE DMT8GVU Hepatitis C virus infection 1E51.1 Phase 2 [19]
LY3556050 DMTW2XB Chronic low-back pain MG30 Phase 2 [20]
CNTX-0290 DMJPEVA Chronic pain MG30 Phase 1 [21]
FR-121196 DMNRUGA Alzheimer disease 8A20 Terminated [22]
SOMATOSTATIN DMIOFQE Acromegaly 5A60.0 Investigative [4]
Des-AA1,2,5-[D-Trp8,Tyr11]SRIF DM7MZ2V Discovery agent N.A. Investigative [5]
Des-AA1,2,5,12,13-[D-Trp8]SRIF DM1KJAE Discovery agent N.A. Investigative [1]
SRIF-28 DM0OM9L Discovery agent N.A. Investigative [6]
99mTc-MIP-1407 DMYPD5L Neuroendocrine cancer 2B72.1 Investigative [23]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Pasireotide DMHM7JS Cushing disease 5A70 Approved [24]
ODT-8 DMBWO5T N. A. N. A. Phase 3 [1]
FR-121196 DMNRUGA Alzheimer disease 8A20 Terminated [22]
SOMATOSTATIN DMIOFQE Acromegaly 5A60.0 Investigative [4]
Des-AA1,2,5-[D-Trp8,Tyr11]SRIF DM7MZ2V Discovery agent N.A. Investigative [5]
Des-AA1,2,5,12,13-[D-Trp8]SRIF DM1KJAE Discovery agent N.A. Investigative [1]
SRIF-28 DM0OM9L Discovery agent N.A. Investigative [6]
99mTc-MIP-1407 DMYPD5L Neuroendocrine cancer 2B72.1 Investigative [24]
Des-AA1,2,4,12,13-[D-Trp8]SRIF DMMWDC5 Discovery agent N.A. Investigative [1]
Cytotoxin Peptide Conjugate DM7SVLZ Discovery agent N.A. Investigative [7]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Somatostatin receptor type 1 (SSTR1) TTIND6G SSR1_HUMAN Inhibitor [1]
Somatostatin receptor type 2 (SSTR2) TTZ6T9E SSR2_HUMAN Inhibitor [1]
Somatostatin receptor type 3 (SSTR3) TTJX3UE SSR3_HUMAN Inhibitor [1]
Somatostatin receptor type 4 (SSTR4) TTAE1BR SSR4_HUMAN Inhibitor [1]
Somatostatin receptor type 5 (SSTR5) TT2BC4G SSR5_HUMAN Inhibitor [1]

References

1 Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 357).
3 Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
4 Discovery of iodinated somatostatin analogues selective for hsst2 and hsst5 with excellent inhibition of growth hormone and prolactin release from ... J Med Chem. 2005 Oct 20;48(21):6643-52.
5 Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan. J Med Chem. 2005 Jan 27;48(2):507-14.
6 Novel octreotide dicarba-analogues with high affinity and different selectivity for somatostatin receptors. J Med Chem. 2010 Aug 26;53(16):6188-97.
7 An adjustable release rate linking strategy for cytotoxin-peptide conjugates. Bioorg Med Chem Lett. 2003 Mar 10;13(5):799-803.
8 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 355).
9 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
10 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 356).
11 Versatile conjugation of octreotide to dendrimers by cycloaddition ("click") chemistry to yield high-affinity multivalent cyclic Peptide dendrimers. Bioconjug Chem. 2009 Jul;20(7):1323-31.
12 Treatment strategies for acromegaly. Expert Opin Emerg Drugs. 2005 Nov;10(4):875-90.
13 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
14 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
15 Paltusotine, a novel oral once-daily nonpeptide SST2 receptor agonist, suppresses GH and IGF-1 in healthy volunteers. Pituitary. 2022 Apr;25(2):328-339.
16 TBR-760, a Dopamine-Somatostatin Compound, Arrests Growth of Aggressive Nonfunctioning Pituitary Adenomas in Mice. Endocrinology. 2020 Aug 1;161(8):bqaa101.
17 The somatostatin analog 188Re-P2045 inhibits the growth of AR42J pancreatic tumor xenografts. J Nucl Med. 2014 Dec;55(12):2020-5.
18 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
19 New Drug in Development Shows Improved Progression-Free Survival for Patients with Advanced Metastatic Midgut Neuroendocrine Tumors
20 ClinicalTrials.gov (NCT04874636) Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3556050 for the Treatment of Chronic Low Back Pain. U.S.National Institutes of Health.
21 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
22 Role of somatostatin in the augmentation of hippocampal long-term potentiation by FR121196, a putative cognitive enhancer. Eur J Pharmacol. 1993 Sep 7;241(1):27-34.
23 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 358).
24 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 359).